Guerbet Appoints Karim Boussebaa as New CEO

Boussebaa brings over 25 years of experience in healthcare and medical technology sectors

Jan. 29, 2026 at 3:47am

Got story updates? Submit your updates here. ›

Guerbet, a global specialist in contrast agents and solutions for medical imaging, has appointed Karim Boussebaa as its new Chief Executive Officer. Boussebaa, a graduate of the École Nationale Supérieure des Sciences Appliquées et Technologies and holder of an MBA from Westminster College in Salt Lake City, Utah, has over 25 years of international experience in the healthcare and medical technology sectors. He previously held executive positions within leading groups, where he led transformation, innovation, and growth programs in the fields of medical imaging and medical devices.

Why it matters

Guerbet is a major player in the medical imaging industry, and Boussebaa's appointment reflects the company's desire to strengthen its operational and strategic management and accelerate its adaptation to a demanding and rapidly evolving market environment. His recognized leadership, ability to unite teams, and experience in complex operational environments are expected to be major assets in supporting Guerbet's development and ambitions.

The details

Guerbet's Board of Directors, following the recommendation of the Nominations and Compensation Committee, has decided to appoint Karim Boussebaa as Chief Executive Officer. This appointment will take effect on February 2, 2026. Boussebaa will replace Jérôme Estampes, who has been serving as interim CEO and will resume his role as Group Chief Financial Officer and SVP Business Development & Licensing.

  • Karim Boussebaa's appointment as CEO will take effect on February 2, 2026.
  • Guerbet will publish its 2025 revenue on February 5, 2026, after market close.

The players

Karim Boussebaa

Karim Boussebaa is the newly appointed Chief Executive Officer of Guerbet. He is a graduate of the École Nationale Supérieure des Sciences Appliquées et Technologies and holds an MBA from Westminster College in Salt Lake City, Utah. Boussebaa has over 25 years of international experience in the healthcare and medical technology sectors, and has held executive positions within leading groups, where he led transformation, innovation, and growth programs in the fields of medical imaging and medical devices.

Jérôme Estampes

Jérôme Estampes has been serving as the interim CEO of Guerbet. As of February 2, 2026, he will resume his role as Group Chief Financial Officer and SVP Business Development & Licensing.

Hugues Lecat

Hugues Lecat is the Chairman of the Board of Directors at Guerbet.

Got photos? Submit your photos here. ›

What they’re saying

“Karim's arrival reflects the Group's desire to strengthen its operational and strategic management and to accelerate the company's adaptation to a demanding and rapidly evolving market environment.”

— Hugues Lecat, Chairman of the Board of Directors (biospace.com)

“I am very excited to join Guerbet at a pivotal moment in its history and to bring my international experience and expertise in medical imaging and MedTech to support the Group's development and ambitions”

— Karim Boussebaa (biospace.com)

What’s next

Guerbet will publish its 2025 revenue on February 5, 2026, after market close.

The takeaway

Guerbet's appointment of Karim Boussebaa as its new CEO reflects the company's commitment to strengthening its operational and strategic management in order to adapt to the rapidly evolving medical imaging market. Boussebaa's extensive experience in the healthcare and medical technology sectors is expected to be a valuable asset in driving Guerbet's development and ambitions.